




Handelsbanken

Life Science Innovation seminar 2021





Bio Convergence solves some of the world's biggest health challenges – through the convergence of scientific disciplines such as biology, engineering, computer science and robotics.



BICO by numbers



2,000+
Labs



65+
Countries



12
Companies



1,850+
Publications



35
Offices



900+
Employees



Modern healthcare challenges that shape the future of Bio Convergence.

Preventing future
pandemics is contingent
on the early detection and
monitoring of infectious
diseases.


9 out of 10 drugs in
development fail in clinical
trials. It can take 10 to 12
years to develop a new
drug at a cost of more than
\$2Bn.

A life is lost every hour
of the day due to lack of
organ transplants.



The Bio Convergence Market

Application areas \$150Bn+



Tissue and disease modelling

The tissue engineering market is expected to reach \$28.9Bn by 2027

+14.2% p.a.

Tissue and disease analysis

The cell line development market is expected to reach \$12Bn by 2027

+13.3% p.a.

Tissue and disease diagnostics

The single cell omics market is expected to reach \$6.59Bn by 2027

+15.8% p.a.

The Diagnostics market is expected to reach \$103Bn by 2027

+4.5% p.a.




Our world-leading customers can be found in four major customer segments

Customer group	Main application areas	Selected customers
Universities and research organisations	<ul style="list-style-type: none"> • Human implants (e.g., bone), biomaterials research, cell biology, teaching etc. • Exploratory research that, if successful, will convert to clinical applications • ~600 institutions in 65 countries (>11,000 relevant academic institutions on a global basis) 	
Pharmaceutical companies	<ul style="list-style-type: none"> • Cancer research (in vitro, clinical and preclinical studies), biopharmaceuticals, cell line development for biologics, gene therapy, tissue culture & engineering • Over 50 customers with top 20 pharma's as customers 	
Diagnostic companies	<ul style="list-style-type: none"> • Multiplex assays, lateral flow tests (Point of Care tests), microfluidic devices, IVD assays and array printing • Cancer research, biopharmaceuticals, drug development, gene therapy and tissue culture & engineering • Long relationships and contracts with many of the larger actors in the field 	
Cosmetic companies/ Other	<ul style="list-style-type: none"> • Toxicity and cosmetic tests on human tissues, working with major players in cosmetics and injectables. Early stage for cosmetics with large potential in the next 3-5 years • Wide range of application areas (e.g., packing solutions, car materials, skin tissues and transplants). Large potential in the next 5-10 years 	





**JOIN THE
BIO-CONVERGENCE
REVOLUTION** ➤



BÍCO